Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted to R0 patients.
Elicio Therapeutics’ pancreatic cancer vaccine failed to improve outcomes in a mid-stage study, but the company is seeking funds to move ahead to a larger …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase…
Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2…
Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy…
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results…
